These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 27710762)

  • 1. The Effects of Cannabis on Inpatient Agitation, Aggression, and Length of Stay.
    Johnson JM; Wu CY; Winder GS; Casher MI; Marshall VD; Bostwick JR
    J Dual Diagn; 2016; 12(3-4):244-251. PubMed ID: 27710762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis.
    Gobbi G; Gaudreau PO; Leblanc N
    J Clin Psychopharmacol; 2006 Oct; 26(5):467-73. PubMed ID: 16974186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological treatment of acute agitation or aggression with schizophrenia or bipolar disorder in the inpatient setting.
    Correll CU; Yu X; Xiang Y; Kane JM; Masand P
    Ann Clin Psychiatry; 2017 May; 29(2):92-107. PubMed ID: 28463343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the use of the positive and negative syndrome scale-excited component as a criterion for administration of p.r.n. medication.
    Chaichan W
    J Psychiatr Pract; 2008 Mar; 14(2):105-13. PubMed ID: 18360196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hospital Stay in Synthetic Cannabinoid Users With Bipolar Disorder, Schizophrenia, or Other Psychotic Disorders Compared With Cannabis Users.
    Deng H; Desai PV; Mohite S; Okusaga OO; Zhang XY; Nielsen DA; Kosten TR
    J Stud Alcohol Drugs; 2019 Mar; 80(2):230-235. PubMed ID: 31014468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute behavioral crises in psychiatric inpatients with autism spectrum disorder (ASD): recognition of concomitant medical or non-ASD psychiatric conditions predicts enhanced improvement.
    Guinchat V; Cravero C; Diaz L; Périsse D; Xavier J; Amiet C; Gourfinkel-An I; Bodeau N; Wachtel L; Cohen D; Consoli A
    Res Dev Disabil; 2015 Mar; 38():242-55. PubMed ID: 25575287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder.
    Citrome L
    Int J Clin Pract; 2012 Mar; 66(3):318-25. PubMed ID: 22226343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Study of the Impact of Cannabis on Doses of Discharge Antipsychotic Medication in Individuals with Schizophrenia or Schizoaffective Disorder.
    Babatope T; Chotalia J; Elkhatib R; Mohite S; Shah J; Goddu S; Patel RA; Aimienwanu OR; Patel D; Makanjuola T; Okusaga OO
    Psychiatr Q; 2016 Dec; 87(4):729-737. PubMed ID: 26875104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Search association between cannabis abuse and bipolar disorder: A study on a sample of patients hospitalized for bipolar disorder].
    Kazour F; Awaida C; Souaiby L; Richa S
    Encephale; 2018 Feb; 44(1):14-21. PubMed ID: 27745717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for an agitated-aggressive syndrome in early-onset psychosis correlated with antisocial personality disorder, forensic history, and substance use disorder.
    Huber CG; Hochstrasser L; Meister K; Schimmelmann BG; Lambert M
    Schizophr Res; 2016 Aug; 175(1-3):198-203. PubMed ID: 27117676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association of cannabis use on inpatient psychiatric hospital outcomes.
    Rylander M; Winston HR; Medlin H; Hull M; Nussbaum A
    Am J Drug Alcohol Abuse; 2018; 44(1):73-84. PubMed ID: 28613973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of agitation and aggression in bipolar mania: efficacy of quetiapine.
    Buckley PF; Paulsson B; Brecher M
    J Affect Disord; 2007; 100 Suppl 1():S33-43. PubMed ID: 17376537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics and length of hospital stay among older adults with bipolar disorder, schizophrenia or schizoaffective disorder, depression, and dementia.
    Sajatovic M; Friedman SH; Sabharwal J; Bingham CR
    J Geriatr Psychiatry Neurol; 2004 Mar; 17(1):3-8. PubMed ID: 15018690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of synthetic cannabinoid use on hospital stay in patients with bipolar disorder versus schizophrenia, or other psychotic disorders.
    Deng H; Mohite S; Suchting R; Nielsen DA; Okusaga OO
    Psychiatry Res; 2018 Mar; 261():248-252. PubMed ID: 29329043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of typical and atypical antipsychotic medications in the management of agitation and aggression.
    Buckley PF
    J Clin Psychiatry; 1999; 60 Suppl 10():52-60. PubMed ID: 10340688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opposite relationships between cannabis use and neurocognitive functioning in bipolar disorder and schizophrenia.
    Ringen PA; Vaskinn A; Sundet K; Engh JA; Jónsdóttir H; Simonsen C; Friis S; Opjordsmoen S; Melle I; Andreassen OA
    Psychol Med; 2010 Aug; 40(8):1337-47. PubMed ID: 19891810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of seclusion in a psychiatric acute inpatient unit.
    Tunde-Ayinmode M; Little J
    Australas Psychiatry; 2004 Dec; 12(4):347-51. PubMed ID: 15715806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intramuscular aripiprazole in the control of agitation.
    Currier GW; Citrome LL; Zimbroff DL; Oren D; Manos G; McQuade R; Pikalov AA; Crandall DT
    J Psychiatr Pract; 2007 May; 13(3):159-69. PubMed ID: 17522559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Agitation in the inpatient psychiatric setting: a review of clinical presentation, burden, and treatment.
    Hankin CS; Bronstone A; Koran LM
    J Psychiatr Pract; 2011 May; 17(3):170-85. PubMed ID: 21586995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of severe agitation with olanzapine in 166 patients with schizophrenia, schizoaffective, or bipolar I disorder.
    Lambert M; Huber CG; Naber D; Schacht A; Wagner TT; Hundemer HP; Karow A; Schimmelmann BG
    Pharmacopsychiatry; 2008 Sep; 41(5):182-9. PubMed ID: 18763220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.